ACE inhibitors are the most common medication cause of angioedema, triggering it in roughly 1 in 200 to 1 in 140 people who take them. But they’re far from the only drugs involved. Several widely prescribed medication classes can cause swelling of the lips, tongue, throat, or face, and the mechanism behind the reaction determines how dangerous it is and how it should be treated.
ACE Inhibitors: The Leading Cause
Blood pressure medications ending in “-pril” (lisinopril, enalapril, ramipril, perindopril) cause angioedema in 0.1 to 0.7 percent of people who take them. That sounds small, but these drugs are among the most prescribed in the world, so the total number of affected patients is significant. Unlike allergic reactions that involve histamine, ACE inhibitor angioedema works through a different pathway. These drugs block the breakdown of a substance called bradykinin, which causes blood vessels to leak fluid into surrounding tissues. The result is deep, often dramatic swelling, typically of the lips, tongue, or throat.
What makes ACE inhibitor angioedema particularly tricky is the timing. Most cases develop within the first year of treatment, but reactions can appear years later. One published case involved a man who developed recurring lip and tongue swelling seven years after starting perindopril. This delay means people rarely connect their long-standing medication to a new symptom.
Because the swelling is bradykinin-driven rather than histamine-driven, standard allergy treatments like antihistamines and corticosteroids have no proven benefit. The primary treatment is stopping the drug, managing the airway if swelling threatens breathing, and supportive care. If you’ve experienced angioedema from an ACE inhibitor, the medication needs to be permanently discontinued.
Who Faces Higher Risk From ACE Inhibitors
Black patients face a substantially higher risk. A large study of U.S. veterans found that Black individuals were nearly four times more likely to develop ACE inhibitor angioedema than white patients (relative risk of 3.88). Women also carry elevated risk, at about 1.5 times the rate of men. People with heart failure or coronary artery disease have modestly increased risk as well.
NSAIDs: Aspirin, Ibuprofen, and Naproxen
Nonsteroidal anti-inflammatory drugs are the other major medication group linked to angioedema. This includes over-the-counter options like ibuprofen, naproxen, and aspirin. The most common form of NSAID-triggered angioedema isn’t a true allergy to a specific drug. Instead, it’s a reaction to the way these medications block a particular enzyme (COX-1) involved in inflammation. Because the trigger is the shared mechanism rather than the specific chemical structure, people who react to one NSAID often react to chemically unrelated NSAIDs as well.
NSAID angioedema frequently appears alongside hives and tends to occur in people with underlying allergic tendencies. Unlike ACE inhibitor angioedema, this type involves histamine-related pathways, so antihistamines and corticosteroids are effective treatments. If you’ve had swelling after taking ibuprofen, you should be cautious with all NSAIDs in the same class, not just the one that caused the reaction.
Heart Failure Drug: Sacubitril/Valsartan
Sacubitril/valsartan (sold as Entresto) is a newer heart failure medication that combines a blood pressure drug with a component that, like ACE inhibitors, affects bradykinin breakdown. In the landmark PARADIGM-HF trial of over 8,400 patients, angioedema occurred at a rate of 0.45 percent in the sacubitril/valsartan group during the treatment phase, compared to 0.24 percent in the enalapril (ACE inhibitor) group. The slightly higher rate reflects the drug’s dual mechanism. People with a history of ACE inhibitor angioedema should not take sacubitril/valsartan.
ARBs After ACE Inhibitor Reactions
Angiotensin receptor blockers (ARBs), the medications ending in “-sartan” like losartan or valsartan, are often considered as replacements when someone can’t tolerate an ACE inhibitor. The question of cross-reactivity has been studied in several trials. An updated meta-analysis found that the risk of angioedema with an ARB in patients who previously reacted to an ACE inhibitor was about 2.5 percent, which was not statistically different from placebo. So while a small number of people do react to both drug classes, most patients can safely switch to an ARB. The transition should be monitored, and a washout period between stopping the ACE inhibitor and starting the ARB is standard practice.
Diabetes Medications: DPP-4 Inhibitors
DPP-4 inhibitors (gliptins) used for type 2 diabetes don’t commonly cause angioedema on their own. The problem arises when they’re combined with an ACE inhibitor. Both drugs interfere with bradykinin breakdown through overlapping pathways, and the combination amplifies the risk. In a pooled analysis published in Hypertension, patients taking both an ACE inhibitor and the DPP-4 inhibitor vildagliptin had an angioedema rate of 0.51 percent, roughly ten times the 0.05 percent rate seen with an ACE inhibitor alone. The risk was dose-dependent, appearing at 100 mg per day of vildagliptin but not at 50 mg per day.
If you take a blood pressure drug ending in “-pril” along with a diabetes drug ending in “-gliptin,” this combination is worth discussing with your prescriber, particularly if you’re already in a higher-risk group.
Estrogen-Containing Medications
Birth control pills and hormone replacement therapy containing estrogen can trigger or worsen angioedema. Research from the Journal of Allergy and Clinical Immunology found that estrogen-containing oral contraceptives increase blood levels of both bradykinin and its precursor molecule after three months of use. This is especially relevant for women with hereditary angioedema, where estrogen-containing medications are known to provoke attacks. Progesterone-only options may actually decrease attack frequency, making them a safer alternative for women prone to swelling episodes.
Immune Therapy and Biologic Drugs
Monoclonal antibodies used in cancer treatment can occasionally cause angioedema as part of a broader allergic-type reaction. Case reports have documented eyelid and facial angioedema with immune checkpoint inhibitors like nivolumab, typically appearing after the second or third treatment cycle. These reactions appear to be true immune-mediated (IgE-driven) hypersensitivity rather than bradykinin-related, meaning they may respond to standard allergy treatments. While the overall incidence is low, anyone receiving infusion-based biologic therapy is monitored for these reactions during administration.
Why the Mechanism Matters
Drug-induced angioedema falls into two fundamentally different categories, and knowing which one you’re dealing with changes everything about treatment. Histamine-mediated angioedema, the type caused by NSAIDs and true drug allergies, almost always comes with hives. It responds to antihistamines, corticosteroids, and epinephrine in severe cases. About 90 percent of angioedema cases involve this pathway.
Bradykinin-mediated angioedema, the type caused by ACE inhibitors and amplified by DPP-4 inhibitors, presents as isolated swelling without hives. This distinction is critical because antihistamines and steroids don’t reliably work for bradykinin-driven swelling. The primary intervention is removing the offending drug and protecting the airway if the tongue or throat is involved. Isolated angioedema, occurring without any hives, accounts for roughly 10 percent of cases and should always raise suspicion for a bradykinin-related cause.
If you experience new facial, lip, or tongue swelling while taking any of these medications, the timing relative to when you started the drug, whether hives are present, and which medications you’re on all help determine the cause and guide treatment.